Since the roles of Notch2 overactivity and the potential of its targeting in haematological malignancies [95] and breast cancer [96] have been previously reported, it might be reasonable to consider Notch2 targeting as a part of treatment regimen against these type of cancers as well as a means of protecting bone micro-vasculature during chemotherapy, a possibility which needs further investigation. The gene discussed is NOTCH2; the disease is breast carcinoma.